Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
5 Eating routine Well disposed Snacks to Keep You Fulfilled - 2Astronomers now say the moon is eating up molecules from Earth’s atmosphere
- 3Treason trial of South Sudan's suspended VP is further eroding peace deal, UN experts say
- 4New portrait of the oldest-known supernova | Space photo of the day for March 27, 2026
- 5Trump says Cuba is 'ready to fall' after capture of Venezuela's Maduro
- Plans for ‘stop anywhere’ night buses recommended by government for women’s safety
- Instructions to Warmly greet Discretion and Thoughtfulness
- Which Store is Your Decision ?
- New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- Plane Passenger Allegedly Includes ‘Bomb Threat’ in Hotspot Network Name, Forces Flight to Make Emergency Landing
- More than 3 million eye drops have been recalled from CVS, Walgreens and other national retailers. How to check if yours are safe
- Move. Cheer. Dance. Do the wave. How to tap into the collective joy of 'we mode'
- Why is the Artemis 2 rocket launch different from all other rocket launches?
- The most effective method to Move toward Compensation Conversations for Cutting edge Practice Enrolled Attendants
